First insights into community pharmacy based buprenorphine-naloxone dispensing in Finland

International Journal of Drug Policy

Volumn 24, Issue 5, 2013, Pages 492-497

  Uosukainen, Hanna ^a   Bell, J Simon ^a,b   Laitinen, Kirsti ^a   Tacke, Ulrich ^a,c   Ilomäki, Jenni ^b   Turunen, Juha H O ^d  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d Farenta Oy   (Finland)

Author keywords

Buprenorphine naloxone; Community pharmacy; Opioid substitution treatment

Indexed keywords

BUPRENORPHINE PLUS NALOXONE;

ARTICLE; DRUG DISPENSING; FINLAND; HEALTH CARE QUALITY; HEALTH SERVICE; HUMAN; MEDICAL EDUCATION; MEDICAL PRACTICE; OPIATE SUBSTITUTION TREATMENT; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PHARMACIST; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; REIMBURSEMENT; REMUNERATION; SOCIAL INSURANCE; TASK PERFORMANCE;

BUPRENORPHINE-NALOXONE; COMMUNITY PHARMACY; OPIOID SUBSTITUTION TREATMENT;

ATTITUDE OF HEALTH PERSONNEL; BUPRENORPHINE; COMMUNITY PHARMACY SERVICES; FINLAND; HUMANS; NALOXONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS;

EID: 84884587902     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2013.02.004     Document Type: Article

References (32)

1. Anstice S., Strike C.J., Brands B. Supervised methadone consumption: Client issues and stigma. Substance Use & Misuse 2009, 44:794-808.
2. Association of Finnish Pharmacies. (2011). Annual review 2011. Retrieved 2nd July 2012 from . http://www.apteekkariliitto.fi/media/pdf/annual_review_2012.pdf.
3. Bell J.S., Väänänen M., Ovaskainen H., Närhi U., Airaksinen M.S. Providing patient care in community pharmacies: Practice and research in Finland. The Annals of Pharmacotherapy 2007, 41:1039-1046.
4. Berbatis C., Sunderland V.B., Bulsara M. The services provided by community pharmacists to prevent, minimise and manage drug misuse: An international perspective. Drug misuse and community pharmacy 2005, 73-83. Taylor & Francis E-library edition. J. Sheridan, J. Strang (Eds.).
5. Buxton J.A., Kuo M.E., Ramji S., Yu A., Krajden M. Methadone use in relation to hepatitis C virus testing in British Columbia. Canadian Journal of Public Health 2010, 101:491-494.
6. European Monitoring Centre for Drugs and Drug Addiction Reviewing current practice in drug-substitution treatment in the European Union 2000, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Insights Series 3, Luxembourg.
7. Ezard N., Lintzeris N., Odgers P., Koutroulis G., Muhleisen P., Stowe A., et al. An evaluation of community methadone services in Victoria, Australia: Results of a client survey. Drug and Alcohol Review 1999, 18:417-423.
8. Fleming G.F., McElnay J.C., Hughes C.M., Sheridan J., Strang J. The role of the community pharmacist in drug abuse: A comparison of service provision between Northern Ireland and England/Wales. Pharmacy World & Science 2001, 23:13-16.
9. Gunderson E.W., Fiellin D.A. Office-based maintenance treatment of opioid dependence: How does it compare with traditional approaches?. CNS Drugs 2008, 22:99-111.
10. Larance B., Degenhardt L., O'Brien S., Lintzeris N., Winstock A., Mattick R.P., et al. Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients. Drug and Alcohol Review 2011, 30:613-620.
11. Lawrie T., Matheson C., Bond C.M., Roberts K. Pharmacy customers' views and experiences of using pharmacies which provide drug misuse services. Drug and Alcohol Review 2004, 23:195-202.
12. Lawrinson P., Roche A., Terao H., Le P.P. Dispensing opioid substitution treatment: Practices, attitudes and intentions of community-based pharmacists. Drug and Alcohol Review 2008, 27:47-53.
13. Lea T., Sheridan J., Winstock A. Consumer satisfaction with opioid treatment services at community pharmacies in Australia. Pharmacy World & Science 2008, 30:940-946.
14. Matheson C., Bond C.M., Mollison J. Attitudinal factors associated with community pharmacists' involvement in services for drug misusers. Addiction 1999, 94:1349-1359.
15. Matheson C., Bond C.M., Pitcairn J. Community pharmacy services for drug misusers in Scotland: What difference does 5 years make?. Addiction 2002, 97:1405-1411.
16. Matheson C., Bond C.M., Tinelli M. Community pharmacy harm reduction services for drug misusers: National service delivery and professional attitude development over a decade in Scotland. Journal of Public Health 2007, 29:350-357.
17. Ministry of Social Affairs and Health. (2008). Decree of the Ministry of Social Affairs and Health on the detoxification and substitution treatment of opioid addicts with certain medicinal products. No. 33/2008.
18. National Advisory Board on Research Ethics in Finland. (2009). Ethical principles of research in the humanities and social and behavioural sciences and proposals for ethical review. Helsinki.
19. National Health Service (NHS) Lothian. (2009). Guidelines for dispensing and supervised self administration of methadone by community pharmacists (3rd ed.). Retrieved 1st October, 2012 from . http://www.communitypharmacy.scot.nhs.uk/documents/nhs_boards/lothian/Lothian-Guidelines-Dispensing-Supervised-Self-Administration-Methadone-pdf.pdf.
20. Neale J. Drug users' views of drug service providers. Health & Social Care in the Community 1998, 6:308-317.
21. Nielsen S., Dietze P., Dunlop A., Muhleisen P., Lee N., Taylor D. Buprenorphine supply by community pharmacists in Victoria, Australia: Perceptions, experiences and key issues identified. Drug and Alcohol Review 2007, 26:143-151.
22. Raisch D.W., Fudala P.J., Saxon A.J., Walsh R., Casadonte P., Ling W., et al. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/naloxone to patients with opioid dependence. Journal of the American Pharmacists Association 2005, 45:23-32.
23. Samitca S., Huissoud T., Jeannin A., Dubois-Arber F. The role of pharmacies in the care of drug users: What has changed in ten years. The case of a Swiss region. European Addiction Research 2007, 13:50-56.
24. Sheridan J., Strang J., Taylor C., Barber N. HIV prevention and drug treatment services for drug misusers: A national study of community pharmacists' attitudes and their involvement in service specific training. Addiction 1997, 92:1737-1748.
25. Sheridan J., Manning V., Ridge G., Mayet S., Strang J. Community pharmacies and the provision of opioid substitution services for drug misusers: Changes in activity and attitudes of community pharmacists across England 1995-2005. Addiction 2007, 102:1824-1830.
26. Sheridan J., Wheeler A., Walters C. Health problems and help-seeking activities of methadone maintenance clients at Auckland Methadone Service (AMS): Potential for community pharmacy service expansion?. Harm Reduction Journal 2005, 2:25.
27. Tanhua, H., Virtanen, A., Knuuti, U., Leppo, A., Kotovirta, A. (2011). Finland - Drug Situation 2011. National report to the EMCDDA by the Reitox National Focal Point, National Institute for Health and Welfare (THL), Report 63/2011.
28. Torre C., Lucas R., Barros H. Syringe exchange in community pharmacies - The Portuguese experience. The International Journal of Drug Policy 2010, 21:514-517.
29. Treloar C., Fraser S., Valentine K. Valuing methadone takeaway doses: The contribution of service-user perspectives to policy and practice. Drugs: Education, Prevention, and Policy 2007, 14:61-74.
30. Uosukainen H., Kauhanen J., Voutilainen S., Föhr J., Paasolainen M., Tiihonen J., et al. Twelve-year trend in treatment seeking for buprenorphine abuse in Finland. Drug and Alcohol Dependence 2013, 127:207-214.
31. Walters C., Raymont A., Galea S., Wheeler A. Evaluation of online training for the provision of opioid substitution treatment by community pharmacists in New Zealand. Drug and Alcohol Review 2012, 31:903-910.
32. Winstock A.R., Lea T., Sheridan J. Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia. Addiction 2010, 105:335-342.